文献速递泌尿男性生殖肿瘤

CHD1缺失通过促进易错双链断裂修复使前列腺癌对DNA损伤治疗敏感

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究通过构建前列腺特异性Chd1缺失的基因工程小鼠模型、同源CHD1野生型与纯合缺失的人良性及前列腺癌细胞系、患者来源类器官培养,并在转移性前列腺癌患者中筛查CHD1缺失,证明CHD1缺失使细胞对DNA损伤敏感并在体内外及患者中产生对DNA损伤治疗的合成致死反应;机制上CHD1调控53BP1稳定性,CHD1缺失导致无差错同源重组修复减少,由易错非同源末端连接修复代偿。

要点

  • CHD1缺失使前列腺癌细胞对DNA损伤治疗产生合成致死反应。
  • CHD1缺失导致同源重组修复减少、非同源末端连接修复代偿增加。
  • CHD1调控53BP1稳定性,其缺失可能贡献该亚型前列腺癌的基因组不稳定。

核心结论

  • 研究首次提供体内和患者证据支持CHD1在双链断裂修复及DNA损伤治疗反应中的作用。
  • CHD1缺失使细胞对DNA损伤敏感并在体外、体内、离体、患者来源类器官及一例转移性前列腺癌患者中产生合成致死反应。
  • CHD1缺失导致无差错同源重组修复减少,由易错非同源末端连接修复代偿,可能贡献该亚型前列腺癌的基因组不稳定。

研究设计与样本

  • 研究构建了前列腺特异性缺失小鼠Chd1的基因工程小鼠模型。
  • 研究使用同源CHD1野生型和纯合缺失的人良性及前列腺癌细胞系。
  • 研究开发了患者来源类器官培养并在转移性前列腺癌患者中筛查CHD1缺失。

主要发现

  • CHD1缺失使细胞对DNA损伤敏感并在体外、体内、离体、患者来源类器官及一例转移性前列腺癌患者中产生合成致死反应。
  • 机制上CHD1调控53BP1稳定性,CHD1缺失导致无差错同源重组修复减少。
  • CHD1缺失后由增加易错非同源末端连接修复代偿双链断裂修复。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deletion of the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1) is a common genomic alteration found in human prostate cancers (PCas). CHD1 loss represents a distinct PCa subtype characterized by SPOP mutation and higher genomic instability. However, the role of CHD1 in PCa development in vivo and its clinical utility remain unclear. PATIENTS AND METHODS: To study the role of CHD1 in PCa development and its loss in clinical management, we generated a genetically engineered mouse model with prostate-specific deletion of murine Chd1 as well as isogenic CHD1 wild-type and homozygous deleted human benign and PCa lines. We also developed patient-derived organoid cultures and screened patients with metastatic PCa for CHD1 loss. RESULTS: We demonstrate that CHD1 loss sensitizes cells to DNA damage and causes a synthetic lethal response to DNA damaging therapy in vitro, in vivo, ex vivo, in patient-derived organoid cultures and in a patient with metastatic PCa. Mechanistically, CHD1 regulates 53BP1 stability and CHD1 loss leads to decreased error-free homologous recombination (HR) repair, which is compensated by increased error-prone non-homologous end joining (NHEJ) repair for DNA double-strand break (DSB) repair. CONCLUSIONS: Our study provides the first in vivo and in patient evidence supporting the role of CHD1 in DSB repair and in response to DNA damaging therapy. We uncover mechanistic insights that CHD1 modulates the choice between HR and NHEJ DSB repair and suggest that CHD1 loss may contribute to the genomic instability seen in this subset of PCas.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Shenoy TR, Boysen G, Wang MY, et al. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol. 2017. PMID: 28383660. doi:10.1093/annonc/mdx165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。